SecurityUTSI / UTStarcom Holdings Corp. (G9310A114)
Institutional Owners31
Institutional Shares1,850,473
Institutional Value$ 9,100,000 USD

Institutional Stock Ownership and Shareholders

UTStarcom Holdings Corp. (NASDAQ:UTSI) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,850,473 shares. Largest shareholders include Renaissance Technologies LLC, Schneider Capital Management Corp, JP Morgan Chase & Co, Geode Capital Management, Llc, Susquehanna International Group, Llp, Macquarie Group Ltd, California Public Employees Retirement System, Arrowstreet Capital, Limited Partnership, O'shaughnessy Asset Management, Llc, and Northern Trust Corp.
UTStarcom Holdings Corp. (NASDAQ:UTSI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 100 0 -100.00 1 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 83,059 0 -100.00 468 0 -100.00
2018-05-15 13F-HR UBS Group AG 2,490 455 -81.73 14 2 -85.71
2017-01-13 13F-HR MetLife Securities, Inc 66 66 0.00 0 0
2018-05-14 13F-HR Renaissance Technologies LLC 1,175,097 1,167,497 -0.65 6,616 5,744 -13.18
2018-05-11 13F-HR MACQUARIE GROUP LTD 51,045 70,345 37.81 287 346 20.56
2018-05-21 13F-HR Navellier & Associates Inc 46,000 0 -100.00 259 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 93,044 95,114 2.22 522 467 -10.54
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 56,178 84,703 50.78 316 417 31.96
2018-04-23 13F-HR Advisory Services Network, LLC 3,529 3,529 0.00 20 17 -15.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 2 2 0.00 0 0
2018-05-15 13F-HR Advisor Group, Inc. 87 3,766 4,228.74 0 18
2018-04-26 13F-HR SIMPLEX TRADING, LLC 233 75 -67.81 1 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 2 0 -100.00 0 0
2018-05-11 13F-HR Russell Investments Group, Ltd. 13,400 66
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 31 21 -32.26 2 0 -100.00
2018-05-14 13F-HR SCHNEIDER CAPITAL MANAGEMENT CORP 246,037 109,175 -55.63 1,385 537 -61.23
2018-05-10 13F-HR JP Morgan Chase & Co 29,921 106,188 254.89 168 522 210.71
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 65,655 65,655 0.00 370 323 -12.70
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 10,100 13,300 31.68 57 65 14.04
2018-05-15 13F-HR WOLVERINE TRADING, LLC 10,855 0 -100.00 61 0 -100.00
2018-05-09 13F-HR ENVESTNET ASSET MANAGEMENT INC 476 2
2018-05-21 13F-HR Front Row Advisors Llc 54 285 427.78 0 1
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 12,075 0 -100.00 68 0 -100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 12,400 12,400 0.00 70 61 -12.86
2018-05-09 13F-HR NORTHERN TRUST CORP 24,539 24,339 -0.82 138 120 -13.04
2018-05-09 13F-HR IFP Advisors, Inc 374 0 -100.00 2 0 -100.00
2018-05-11 13F-HR Delpha Capital Management, Llc 306 0 -100.00 2 0 -100.00
2018-05-14 13F-HR Axa 15,200 75
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 15,100 11,800 -21.85 85 58 -31.76
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 477 433 -9.22 3 2 -33.33
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 3,128 2,777 -11.22 18 14 -22.22
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 0 800 0 4
2018-05-08 13F-HR Parallel Advisors, LLC 83 83 0.00 0 0
2018-05-15 13F-HR WOLVERINE TRADING, LLC Call 17,300 18,600 7.51 97 92 -5.15
2018-05-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 37,151 183
2018-05-08 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 54 24,847 45,912.96 0 122
2018-05-15 13F-HR BARCLAYS PLC 17 0 -100.00 0 0
2018-05-15 13F-HR One Wealth Advisors, Llc 188 1
2018-05-02 13F-HR THOMPSON DAVIS & CO., INC. 750 0 -100.00 4 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 3,167 2,767 -12.63 18 14 -22.22
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 41,735 0 -100.00 235 0 -100.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 215 396 84.19 1 2 100.00
2018-05-03 13F-HR Trexquant Investment LP 16,613 0 -100.00 94 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 114,265 8,361 -92.68 642 40 -93.77
2018-05-10 13F-HR Cavalier Investments 46,000 0 -100.00 259 0 -100.00

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

ACM Research Shares Could Fall When IPO Lockup Expires

2018-04-20 seekingalpha
When the ACM Research IPO lockup expires on May 2nd, pre-IPO shareholders and company insiders can sell large blocks of currently restricted stock for the first time. (6-0)

CUSIP: G9310A114